Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients
Morales, Noppawan Phumala, Rodrat, Supot, Piromkraipak, Pannaree, Yamanont, Paveena, Paiboonsukwong, Kittiphong, Fucharoen, Suthat
Published in Biomedicine & pharmacotherapy (01.01.2022)
Published in Biomedicine & pharmacotherapy (01.01.2022)
Get full text
Journal Article
Comparison of Pharmacokinetics and Urinary Iron Excretion of Two Single Doses of Deferiprone in β-Thalassemia/Hemoglobin E Patients
Rodrat, Supot, Yamanont, Pavena, Tankanitlert, Jeeranut, Chantraraksri, Udom, Fucharoen, Suthat, Morales, Noppawan Phumala
Published in Pharmacology (01.01.2012)
Published in Pharmacology (01.01.2012)
Get full text
Journal Article
Comparison of Pharmacokinetics and Urinary Iron Excretion of Two Single Doses of Deferiprone in [beta]-Thalassemia/Hemoglobin E Patients
Rodrat, Supot, Yamanont, Pavena, Tankanitlert, Jeeranut, Chantraraksri, Udom, Fucharoen, Suthat, Morales, Noppawan Phumala
Published in Pharmacology (01.08.2012)
Published in Pharmacology (01.08.2012)
Get full text
Journal Article
Comparison of Pharmacokinetics and Urinary Iron Excretion of Two Single Doses of Deferiprone in ß-Thalassemia/Hemoglobin E Patients
Rodrat, Supot, Yamanont, Pavena, Tankanitlert, Jeeranut, Chantraraksri, Udom, Fucharoen, Suthat, Morales, Noppawan Phumala
Published in Pharmacology (2012)
Published in Pharmacology (2012)
Get full text
Journal Article